Pulvinar Neuro is both honored and thrilled to share that we have been awarded a three-year, $3.06 million Phase II SBIR Grant from the NIH's National Institute of Mental Health (NIMH). 

For more information, please click here.

Pulvinar Neuro, in partnership with Electromedical Products International, Inc. (EPI), is excited to announce that Dr. Leah Townsend, President of Pulvinar Neuro and Chief Science Officer of EPI, will be attending the 5th International Brain Stimulation Conference in Lisbon, Portugal (Saturday, February 18, 2023 - Wednesday, February 22, 2023). Dr. Townsend will have Pulvinar's next-generation research device, XCSITE-RD at Booth #29.

Stop by if you're attending to meet Dr. Townsend and discuss the future of non-invasive brain stimulation in psychiatry!

We are excited to announce a strategic partnership with Electromedical Products International, Inc. (EPI), a leading medical device company using non-invasive brain stimulation to treat psychiatric disorders. This partnership will allow us to accelerate our non-invasive brain stimulation and product development, including transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled therapeutics for the treatment of psychiatric and neurological illnesses.

EPI is the market leader in low-current, non-invasive brain stimulation and has a long-standing track record of marketing its patented, FDA-cleared Alpha-Stim technology for the treatment of anxiety, insomnia, depression, and pain. 

We are pleased to announce that Dr. Leah Townsend, PhD has joined us as Chief Executive Officer of Pulvinar Neuro. She previously served as a business consultant for Pulvinar Neuro and was instrumental in winning our Phase I NIMH grant (R43MH119872) to develop closed-loop tACS.